Evidence map›Paper›PMID 33910514›Full record

ArticleBMC infectious diseases2021

Developing and validating a risk algorithm to diagnose Neisseria gonorrhoeae and Chlamydia trachomatis in symptomatic Rwandan women.

Kristin M Wall, Julien Nyombayire, Rachel Parker, Rosine Ingabire, Jean Bizimana, Jeannine Mukamuyango, Amelia Mazzei, Matt A Price, Marie Aimee Unyuzimana, Amanda Tichacek and 2 more

Open access · goldAbstract readValidation Study
In one paragraph

Article in BMC infectious diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Kristin M WallRwanda Zambia HIV Research Group, Department of Pathology & Laboratory Medicine, School of Medicine and Hubert Department of Global Health and Department of Epidemiology, Rollins School of Public Health, Laney Graduate School, Emory University, 1518 Clifton Road NE, Atlanta, GA, 30322, USA. kmwall@emory.edu.
Julien NyombayireProjet San Francisco, Rwanda Zambia HIV Research Group, Kigali, Rwanda.
Rachel ParkerRwanda Zambia HIV Research Group, Department of Pathology & Laboratory Medicine, School of Medicine and Hubert Department of Global Health and Department of Epidemiology, Rollins School of Public Health, Laney Graduate School, Emory University, 1518 Clifton Road NE, Atlanta, GA, 30322, USA.
Rosine IngabireProjet San Francisco, Rwanda Zambia HIV Research Group, Kigali, Rwanda.
Jean BizimanaProjet San Francisco, Rwanda Zambia HIV Research Group, Kigali, Rwanda.
Jeannine MukamuyangoProjet San Francisco, Rwanda Zambia HIV Research Group, Kigali, Rwanda.
Amelia MazzeiProjet San Francisco, Rwanda Zambia HIV Research Group, Kigali, Rwanda.
Matt A PriceIAVI, NY, NY, University of California San Francisco, San Francisco, CA, 94115, USA.
Marie Aimee UnyuzimanaProjet San Francisco, Rwanda Zambia HIV Research Group, Kigali, Rwanda.
Amanda TichacekRwanda Zambia HIV Research Group, Department of Pathology & Laboratory Medicine, School of Medicine and Hubert Department of Global Health and Department of Epidemiology, Rollins School of Public Health, Laney Graduate School, Emory University, 1518 Clifton Road NE, Atlanta, GA, 30322, USA.
Susan AllenRwanda Zambia HIV Research Group, Department of Pathology & Laboratory Medicine, School of Medicine and Hubert Department of Global Health and Department of Epidemiology, Rollins School of Public Health, Laney Graduate School, Emory University, 1518 Clifton Road NE, Atlanta, GA, 30322, USA.
Etienne KaritaProjet San Francisco, Rwanda Zambia HIV Research Group, Kigali, Rwanda.
Rwanda Zambia HIV Research Group · RWEmory University · USUniversity of California, San Francisco · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAlgorithms that bridge the gap between syndromic sexually transmitted infection (STI) management and treatment based in realistic diagnostic options and local epidemiology are urgently needed across Africa. Our objective was to develop and validate a risk algorithm for Neisseria gonorrhoeae (NG) and Chlamydia trachomatis (CT) diagnosis among symptomatic Rwandan women and to compare risk algorithm performance to the current Rwandan National Criteria for NG/CT diagnosis.

methodsThe risk algorithm was derived in a cohort (n = 468) comprised of symptomatic women in Kigali who sought free screening and treatment for sexually transmitted infections and vaginal dysbioses at our research site. We used logistic regression to derive a risk algorithm for prediction of NG/CT infection. Ten-fold cross-validation internally validated the risk algorithm. We applied the risk algorithm to an external validation cohort also comprised of symptomatic Rwandan women (n = 305). Measures of calibration, discrimination, and screening performance of our risk algorithm compared to the current Rwandan National Criteria are presented.

resultsThe prevalence of NG/CT in the derivation cohort was 34.6%. The risk algorithm included: age < =25, having no/primary education, not having full-time employment, using condoms only sometimes, not reporting genital itching, testing negative for vaginal candida, and testing positive for bacterial vaginosis. The model was well calibrated (Hosmer-Lemeshow p = 0.831). Higher risk scores were significantly associated with increased prevalence of NG/CT infection (p < 0.001). Using a cut-point score of > = 5, the risk algorithm had a sensitivity of 81%, specificity of 54%, positive predictive value (PPV) of 48%, and negative predictive value (NPV) of 85%. Internal and external validation showed similar predictive ability of the risk algorithm, which outperformed the Rwandan National Criteria. Applying the Rwandan National Criteria cutoff of > = 2 (the current cutoff) to our derivation cohort had a sensitivity of 26%, specificity of 89%, PPV of 55%, and NPV of 69%.

conclusionsThese data support use of a locally relevant, evidence-based risk algorithm to significantly reduce the number of untreated NG/CT cases in symptomatic Rwandan women. The risk algorithm could be a cost-effective way to target treatment to those at highest NG/CT risk. The algorithm could also aid in sexually transmitted infection risk and prevention communication between providers and clients.

Indexed as

AlgorithmsChlamydia trachomatisNeisseria gonorrhoeaeAdultChlamydia InfectionsFemaleGonorrheaHumansLogistic ModelsMass ScreeningPredictive Value of TestsPrevalenceRisk FactorsRwandaSensitivity and SpecificityYoung AdultChlamydia trachomatisNeisseria gonorrhoeaeRisk algorithmRwanda

Identifiers

PMID33910514
PMCPMC8080377
OpenAlexW3158404634

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.